Group One Trading’s Keros Therapeutics KROS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.1K Buy
+734
New +$11.3K ﹤0.01% 6478
2025
Q4
Sell
-14,483
Closed -$254K 8677
2025
Q3
$229K Sell
14,483
-8,548
-37% -$126K ﹤0.01% 4542
2025
Q2
$307K Sell
23,031
-26,663
-54% -$360K ﹤0.01% 3905
2025
Q1
$506K Buy
49,694
+48,594
+4,418% +$564K ﹤0.01% 3070
2024
Q4
$17.4K Buy
+1,100
New +$57.2K ﹤0.01% 5781
2022
Q3
Sell
-100
Closed -$3.47K 7886
2022
Q2
$3K Buy
+100
New +$4.39K ﹤0.01% 7301

Other funds holding KROS

Group One Trading's KROS Position: Q1 2026 in Review

Group One Trading opened a new position in Keros Therapeutics (KROS) in Q1 2026: 734 shares worth $8.1K. The stake represents ﹤0.01% of the portfolio and ranks #6478 among its holdings. This is a return to the name: Group One Trading previously reported a position in KROS as recently as Q3 2025.

Group One Trading first reported a position in KROS in Q2 2022 and has held it in 6 quarters since. The position peaked at $506K in Q1 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Group One Trading held 734 shares of Keros Therapeutics worth $8.1K as of Q1 2026.
  • Keros Therapeutics was a new Group One Trading position in Q1 2026.
  • Keros Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6478 holding.
  • Group One Trading first reported a position in Keros Therapeutics in Q2 2022 and has held it in 6 quarters since.
  • Group One Trading's Keros Therapeutics position peaked at $506K in Q1 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.